M-EZETIMIBE TABLET

Država: Kanada

Jezik: angleščina

Source: Health Canada

Kupite ga zdaj

Prenos Lastnosti izdelka (SPC)
30-05-2023

Aktivna sestavina:

EZETIMIBE

Dostopno od:

MANTRA PHARMA INC

Koda artikla:

C10AX09

INN (mednarodno ime):

EZETIMIBE

Odmerek:

10MG

Farmacevtska oblika:

TABLET

Sestava:

EZETIMIBE 10MG

Pot uporabe:

ORAL

Enote v paketu:

100/500

Tip zastaranja:

Prescription

Terapevtsko območje:

CHOLESTEROL ABSORPTION INHIBITORS

Povzetek izdelek:

Active ingredient group (AIG) number: 0149164001; AHFS:

Status dovoljenje:

APPROVED

Datum dovoljenje:

2017-08-18

Lastnosti izdelka

                                Page
1
of
30
PRODUCT MONOGRAPH
PR
M-EZETIMIBE
Ezetimibe Tablets, USP
10 mg
Cholesterol Absorption Inhibitor
Mantra Pharma Inc.,
1000 du Lux, suite 201
Brossard, Quebec
J4Y 0E3
Control # 275104
Date
of
Revision:
MAY
30, 2023
Page
2
of
30
TABLE OF CONTENT
Table of Content
.....................................................................................................................................2
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................................3
SUMMARY PRODUCT INFORMATION
...........................................................................................3
INDICATIONS AND CLINICAL USE
............................................................................................3
CONTRAINDICATIONS
.................................................................................................................4
WARNINGS AND PRECAUTIONS
................................................................................................4
ADVERSE REACTIONS
.................................................................................................................7
DRUG INTERACTIONS
................................................................................................................11
DOSAGE AND ADMINISTRATION
............................................................................................13
OVERDOSAGE
..............................................................................................................................14
ACTION AND CLINICAL PHARMACOLOGY
..........................................................................14
STORAGE AND STABILITY
........................................................................................................16
DOSAGE FORMS, COMPOSITION AND PACKAGING
...........................................................16
PART II: SCIENTIFIC INFORMATION
............................................................................................17
PHARMACEUTICAL INFORMATION
.......
                                
                                Preberite celoten dokument
                                
                            

Dokumenti v drugih jezikih

Lastnosti izdelka Lastnosti izdelka francoščina 30-05-2023

Opozorila o iskanju, povezana s tem izdelkom